Haleon PLC Sponsored ADR $HLN Shares Sold by DAVENPORT & Co LLC

DAVENPORT & Co LLC cut its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 24.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 223,716 shares of the company’s stock after selling 71,258 shares during the period. DAVENPORT & Co LLC’s holdings in Haleon were worth $2,007,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Private Trust Co. NA grew its position in Haleon by 13.3% during the second quarter. Private Trust Co. NA now owns 8,794 shares of the company’s stock valued at $91,000 after acquiring an additional 1,032 shares during the period. Cary Street Partners Financial LLC lifted its stake in shares of Haleon by 20.1% in the 2nd quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after purchasing an additional 1,113 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Haleon by 4.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 31,423 shares of the company’s stock worth $321,000 after purchasing an additional 1,200 shares during the period. Geneos Wealth Management Inc. grew its holdings in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the period. Finally, First Horizon Advisors Inc. increased its position in Haleon by 8.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 17,549 shares of the company’s stock worth $182,000 after purchasing an additional 1,302 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on HLN. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Finally, Barclays downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Haleon presently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Stock Up 0.3%

Shares of Haleon stock opened at $10.14 on Friday. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The company has a market capitalization of $45.13 billion, a PE ratio of 25.99 and a beta of 0.20. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The business has a 50-day moving average of $9.60 and a 200-day moving average of $9.67.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.